USPTO Trademark 98757000
USPTO Trademark 98757000 is a USPTO trademark filed by Sarepta Therapeutics, Inc.. Status: Pending.
Trademark Facts
| Mark | USPTO Trademark 98757000 |
|---|---|
| Serial Number | 98757000 |
| Status | Pending |
| Filing Date | 2024-09-18 |
| Mark Type | Design |
| Nice Classes | 001 (Chemicals), 005 (Pharmaceuticals), 011 (HVAC & Lighting), 041 (Education & Entertainment), 044 (Medical Services) |
| Owner | Sarepta Therapeutics, Inc. |
| Attorney of Record | Maury M. Tepper, III |
| Prosecution Events | 19 |
| Latest Event | EXRA on 2026-01-09 |
Goods & Services
Medical training and teaching; Pharmaceutical preparations for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations based on morpholino oligomer technology platform for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders, and for the regulation of protein production; Pharmaceutical preparations that modulate RNA expression for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders, and for the regulation of protein production; Gene therapy products, namely, gene delivery pharmaceuticals for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations for gene therapy, gene editing, and genome editing for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Gene therapies, in the nature of pharmaceuticals for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Biological preparations for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Viral vaccines and viral vectors vaccines for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations, biological preparations and gene therapy products in the nature of pharmaceutical and biological preparations for the treatment of genetic disorders and diseases; Viruses, viral vectors, and viral constructs for use in the manufacture of pharmaceuticals for the treatment of neuromuscular diseases and disorders.; Medical services; providing health information